Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05147467 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Sep 2024 to Dec 2026 Completion date: Dec 2024 to Dec 2027 · Site details revised at 10 of 11 sitesv8 Show 2 more changesShow less
    • Completion date: Dec 2024 to Dec 2027
    • Site details revised at 10 of 11 sites
  2. Primary completion date: Oct 2023 to Sep 2024 Completion date: Jan 2024 to Dec 2024 · Start date: Mar 10, 2022 to Dec 28, 2021v7 Show 2 more changesShow less
    • Completion date: Jan 2024 to Dec 2024
    • Start date: Mar 10, 2022 to Dec 28, 2021
  3. Study sites: 53 to 11 Eligibility criteria shortened, about 344 wordsv6 Show 1 more changeShow less
    • Eligibility criteria shortened, about 344 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 46 to 53v5
  5. Study sites: 34 to 46v4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting Study sites: 2 to 34 · Start date changed from estimate of Jan 2022 to Mar 10, 2022 · Eligibility criteria shortened, about 10 wordsv3 Show 3 more changesShow less
    • Study sites: 2 to 34
    • Start date changed from estimate of Jan 2022 to Mar 10, 2022
    • Eligibility criteria shortened, about 10 words

    See this version in full on ClinicalTrials.gov ↗

  2. Secondary endpoints revised (9)v2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL.
Trial Details
NCT Number NCT05147467
Lead Sponsor Ascentage Pharma Group Inc.
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov